Related by context. All words. (Click for frequent words.) 71 prognostic indicators 68 Prognostic factors 68 prognostic marker 67 prostate cancer CaP 67 prognostic indicator 66 chemosensitivity 66 prognostic significance 66 hyperplastic polyps 66 KRAS mutation 65 breast cancer subtypes 65 prognostic biomarker 65 pre malignant lesions 65 mucinous 65 HER2 expression 65 FGFs 64 stratifying patients 64 epithelial tumors 64 angiographically 64 K ras mutations 64 immunohistochemical analysis 64 tumor subtypes 64 mechanistic studies 64 biologic plausibility 64 prognostic markers 64 pleiotropic effects 64 urine cytology 64 biologic pathways 64 immunological responses 63 circulating endothelial cells 63 malignant nodules 63 Akt activation 63 carotid plaques 63 radiographic findings 63 APOE genotype 63 liver metastasis 63 genomic alterations 63 NPM1 mutation 63 apolipoproteins 63 S. maltophilia 63 LDL HDL 63 serologic tests 63 etiologic 62 mitochondrial metabolism 62 EGFR mutation status 62 oncologic outcomes 62 CYP #D# 62 DNA methylation patterns 62 prognostic factor 62 prognostic variables 62 histone deacetylases 62 antiangiogenic therapy 62 chromosomal rearrangement 62 PCa 62 tumorigenicity 62 prostate carcinoma 62 differential gene expression 62 relapsed SCLC 62 antitumor effect 62 kinase inhibition 62 tumoral 62 seminomas 62 hematopoietic cancers 62 Gram stain 62 AST ALT 62 molecular subtypes 62 pelvic lymphadenectomy 62 lipoprotein metabolism 62 Lymph node 62 plasma lipid 62 renal tumors 62 clinicopathological 62 prophylactic cranial irradiation 62 putative biomarkers 62 gene amplification 62 transrectal ultrasound guided 62 histologies 62 hormone receptor status 62 physico chemical properties 62 histologic findings 62 transgene expression 62 fibrotic disease 61 phenotypic expression 61 histological subtype 61 nonvascular 61 ConclusionThis 61 adjuvant therapies 61 differentiated thyroid 61 serum lipid 61 ovarian carcinoma 61 myeloproliferative diseases 61 gene rearrangements 61 chromosomal mutations 61 carotid plaque 61 pharmacodynamic biomarkers 61 pharmacologic intervention 61 clinicopathologic 61 tumor histology 61 cytologic 61 underlying pathophysiology 61 scintigraphic 61 quasispecies 61 Leydig cell 61 metabolite concentrations 61 mycobacterial 61 miRNA expression 61 murine models 61 immunosuppressive regimen 61 Haptoglobin 61 serum PTH 61 immunohistochemical 61 pharmacodynamic parameters 61 natriuretic peptides 61 surrogate markers 61 Cyclin E 61 micrometastasis 61 Tr DNA 61 anaerobes 61 histopathologic 61 lipoprotein profiles 61 familial clustering 61 receptor inhibitor 61 lactate dehydrogenase LDH 61 thyroglobulin 61 FDG PET imaging 61 FDG uptake 61 N glycan 61 osteoblastic 61 isotypes 61 prostate cancer PCa 61 nomograms 61 gastric adenocarcinoma 61 clonogenic 61 IgG4 61 neoplastic 61 p# activation 61 spontaneous regression 61 virulence genes 61 prostate carcinogenesis 61 hematological parameters 61 cervical lymph nodes 60 induced sputum 60 histologic subtype 60 operable breast cancer 60 malignant lesions 60 Hedgehog inhibitor 60 immunomodulation 60 methylation patterns 60 perioperative morbidity 60 Randomized trials 60 MAPK pathway 60 mammographically 60 clinically insignificant 60 alkaline phosphatase ALP 60 Membrane proteins 60 multiplex assay 60 androgen signaling 60 Histologically 60 serum PSA 60 survivin expression 60 metastatic neuroendocrine tumors 60 lymphoproliferative disorders 60 preoperative diagnosis 60 hepatocellular carcinomas 60 TMPRSS2 ERG fusion 60 cAMP pathway 60 telomere lengths 60 multivariate regression analysis 60 EBV infection 60 idiopathic myelofibrosis 60 T#I [002] 60 haematopoietic 60 modifier genes 60 carcinoids 60 metastatic lymph nodes 60 adenomatous polyps 60 unmeasured confounding 60 abnormal glucose metabolism 60 gene loci 60 obstructive coronary artery 60 pulmonary metastases 60 immune modulating 60 mutated K ras 60 airway hyperresponsiveness 60 ERK signaling 60 carotid IMT 60 diagnostic biomarker 60 bronchopulmonary dysplasia BPD 60 hypericin 60 Genetic variations 60 RQ PCR 60 genetic polymorphisms 60 myelofibrosis polycythemia vera 60 multicentric 60 gene polymorphisms 60 infecting organism 60 immunochemical fecal occult 60 epistasis 60 serological tests 60 tumor subtype 60 pharmacokinetic interactions 60 ABCB1 60 HER2 positivity 60 biomarker identification 60 histologic subtypes 60 pleiotropic 60 hypoxic tumors 60 prion infection 60 nodal metastases 60 Hormone receptor 60 N. gonorrhoeae 60 HIV tropism 60 p# Shc 60 epidemiologically 60 anti angiogenic agents 60 surgically resectable 60 serum biomarkers 60 hepatic fibrosis 60 histopathological 59 metabolic parameters 59 ARF1 59 Genetic predisposition 59 indolent lymphomas 59 BRAF V#E mutation 59 histone modifications 59 EGFR tyrosine kinase inhibitors 59 etiologic factors 59 oncoproteins 59 Dietary restriction 59 radiochemotherapy 59 renal cysts 59 K ras mutation 59 Estrogen Receptor 59 HIV HCV coinfected 59 endocervical 59 Zevalin consolidation 59 prostatic adenocarcinoma 59 conserved sequences 59 BEXXAR Therapeutic Regimen 59 spirometric 59 KRAS mutation status 59 antitumour activity 59 quantitate 59 preoperative staging 59 genetic aberrations 59 gastric carcinoma 59 ERBB2 59 immunocompetent 59 hamartomas 59 antitumor efficacy 59 lobular carcinoma 59 colorectal adenoma 59 hENT1 59 cranial irradiation 59 bronchial epithelial cells 59 glucose abnormalities 59 HER2 overexpression 59 secretory pathway 59 Umbilical cord stem cells 59 pancreatic adenocarcinoma 59 neuropathologic 59 antibody mediated 59 pCR 59 PSADT 59 HER2 positive cancers 59 mechanistic insights 59 MTHFR gene 59 DNA demethylation 59 intraobserver 59 genetic loci 59 interobserver 59 nucleic acids proteins 59 hematopoietic malignancies 59 squamous cell lung cancer 59 CSF biomarkers 59 missense mutations 59 genotypic resistance 59 antibody titer 59 GIST tumors 59 Polycythemia vera 59 FDG-PET/CT 59 BRCA mutation carriers 59 CYP #A# 59 impair fertility 59 colorectal adenocarcinoma 59 biopsied tissue 59 penetrance 59 ABL1 59 immunosuppressive regimens 59 F FDG PET 59 microRNA biomarkers 59 binding affinities 59 histologically 59 epigenetic mechanisms 59 T2DM 59 vascularisation 59 p# mutations 59 molecular mimicry 59 phenotypic characteristics 59 nonalcoholic steatohepatitis NASH 59 antiangiogenic agents 59 CD# expression [002] 59 imatinib resistance 59 convergent validity 59 haematologic 59 mTOR inhibitors 59 lipid abnormalities 59 molecular biomarkers 59 urothelial cancer 59 Flow cytometry 59 Gleevec resistant 59 tumor necrosis 59 colorectal liver metastases 59 elevated CRP 59 immunoregulatory 59 cervical carcinoma 59 ADPKD 59 serous ovarian cancer 59 Flt3 59 prehospital setting 59 serum antibodies 59 clonal expansion 59 florbetaben 59 estrogen receptor ER 59 thyroid carcinoma 59 somatic mutations 59 cisplatin resistant 59 hormone refractory 59 #F FDG PET 59 demyelinating 59 extracapsular extension 59 antioxidant supplementation 59 microbiomes 59 atherothrombotic 59 cytologically 59 precursor lesions 59 node metastases 59 biochemical abnormalities 59 univariate 59 PARP inhibition 59 urothelial carcinoma 59 pituitary adenomas 59 physicochemical properties 59 molecularly defined 59 completely resected 59 B7 H3 59 unmeasured confounders 59 tumor biopsies 59 lymph node dissection 59 abnormal cytology 59 VEGF expression 59 replicase 59 cellular prion protein 59 co receptor tropism 59 leiomyomas 59 humoral responses 59 Sjögren syndrome 59 obstructive coronary 59 immunostaining 59 flavopiridol 59 eTag assays 59 atherosclerotic lesions 59 non squamous histology 59 functional polymorphism 59 echocardiographic parameters 59 IDH mutations 58 osteosarcomas 58 coronary anatomy 58 cardiac troponin 58 thyroid nodules 58 mutational status 58 dosimetric 58 P. falciparum parasites 58 posttranslational modifications 58 C. albicans 58 ESBLs 58 TMPRSS2 ERG 58 β blockers 58 VDAs 58 SLNB 58 coinfected patients 58 locoregional 58 hypercoagulable 58 bronchoalveolar lavage 58 Leukemias 58 monogenic 58 xenograft models 58 Cystatin C 58 genetic determinants 58 PET tracers 58 metastatic lesion 58 plasma lipoprotein 58 clinico pathological 58 System IPSS 58 Radical prostatectomy 58 M. pneumoniae 58 chemoprevention trials 58 histologic 58 coinfection 58 Systemic lupus erythematosus 58 genotypic 58 epigenetic therapies 58 S. sanguinis 58 reproducible measurements 58 HMGCR 58 GISTs 58 Treg cell 58 Hematologic toxicity 58 fungal genomes 58 lowering blood glucose 58 myopathies 58 D dimer 58 NPM1 mutations 58 Genetic variants 58 HCV replication 58 genotype phenotype 58 pleiotropy 58 pro angiogenic 58 ImmuKnow 58 colorectal carcinoma 58 antibiotic susceptibility 58 EGFR blockers 58 metaplasia 58 Venous thromboembolism 58 LHRH receptor positive 58 subclinical atherosclerosis 58 Clusterin 58 curative therapy 58 antiproliferative effects 58 thyroid nodule 58 metastatic RCC 58 mammographic density 58 chromosome aberrations 58 Prenatal diagnosis 58 colorectal carcinogenesis 58 immunohistochemical staining 58 AtherOx 58 microRNA expression 58 PNH patients 58 SSc 58 antiphospholipid syndrome 58 colonoscopic 58 Subgroup analyzes 58 tryptase 58 CD#c 58 atherogenic dyslipidemia 58 diagnostically 58 TT genotype 58 CP CPPS 58 Endothelial dysfunction 58 micrometastases 58 chemoresistant 58 inflammatory biomarkers 58 endometrial biopsy 58 ASCUS 58 hoFH patients 58 waist circumference WC 58 EGFR mutation positive 58 endothelial activation 58 lymphoid cells 58 sputum cytology 58 electrophysiologic 58 mediated inhibition 58 fluoroquinolone resistance 58 physiologic mechanisms 58 VKORC1 58 multivariate analyzes 58 pathogenic mechanisms 58 Tasigna prolongs 58 Cardiotoxicity 58 PDE7B 58 prospective multicenter study 58 aminotransferase 58 p# MAPK 58 germline mutations 58 E. faecalis 58 immunochemical 58 viral tropism 58 GRP# 58 diagnostic modality 58 T SPOT.TB 58 gastric cardia 58 EGFR mutations 58 morphologic 58 malignant growths 58 Uncontrolled hypertension 58 Hurthle cell 58 tumor hypoxia 58 antiphospholipid antibodies 58 BRAF mutation 58 KRAS mutant 58 percutaneous biopsy 58 ultrastructure 58 sarcomatoid 58 androgen receptor AR 58 sentinel lymph node biopsy 58 Adjuvant chemotherapy 58 Mycobacterium smegmatis 58 oncological outcomes 58 predictive biomarker 58 adverse cytogenetics 58 carcinoid 58 acetabular fractures 58 human leukocyte antigens 58 CYT# potent vascular disrupting 58 lymphomas leukemias 58 peritoneal carcinomatosis 58 cTnI 58 pathologic diagnosis 58 cellularity 58 SMAD4 58 renal fibrosis 58 methyltransferases 58 intravesical therapy 58 endoscopic ultrasonography 58 skeletal metastases 58 radiotherapy RT 58 cathepsin K 58 SOCS2 58 surrogate marker 58 Zollinger Ellison Syndrome 58 arterial calcification 58 CD# expression [001] 58 hyperplastic 58 clefting 58 PECAM 1 58 atherogenic 58 CYP#D# genotype 58 generalisable 58 primary aldosteronism 58 molecular abnormalities 58 myeloablative 58 UGT#A# 58 T1a 58 patient subpopulations 58 endophenotypes 58 intracellular bacteria 58 intestinal permeability 58 chlamydial infection 58 CORE OM 58 cortical excitability 58 nucleosome positioning 58 locoregional recurrence 58 intact parathyroid hormone 58 Xenopus embryos 58 prostate epithelial cells 58 refractory colorectal cancer 58 K ras gene 58 methylation markers 58 promoter methylation 58 PON1 58 proteomes 57 anti angiogenic drugs 57 histologic diagnosis 57 hormone receptor negative 57 mTOR inhibition 57 premalignant 57 pleural fluid 57 neurocognitive function 57 empiric treatment 57 synovial cells 57 STAT3 signaling 57 melanocytic 57 intima media thickness 57 5alpha reductase 57 colonic polyps 57 TOP2A 57 MMP inhibitors 57 nucleotide substitutions 57 nonpharmacologic 57 Poisson regression 57 antibiotic regimens 57 polyp recurrence 57 ventricular myocardium 57 aetiology 57 cardiotoxicity 57 extramedullary 57 taxane therapy 57 pharmacodynamic PD 57 cathepsins 57 p# biomarker 57 Radiofrequency ablation 57 xenobiotic 57 LVNC 57 nanoscale phenomena 57 gastric mucosa 57 granzyme B 57 RT qPCR 57 phylogenetically 57 gadolinium enhanced 57 PITX2 57 histopathologic examination 57 IV bisphosphonates 57 metabolomic profiles 57 chromosomal instability 57 antiangiogenic agent 57 LV dysfunction 57 peritoneal fluid 57 glomerular filtration 57 riociguat 57 albumin excretion rate 57 remnant lipoproteins 57 CagA 57 coding genes 57 Elevated serum 57 esophagogastric 57 BHD Syndrome 57 IGF IR 57 Evolutionarily speaking 57 Virulizin ® 57 pulmonary nodules 57 metabonomics 57 cTnT 57 delafloxacin 57 chromosomal aberrations 57 neoplasm 57 malignant lymphomas 57 progesterone receptor PR 57 homodimers 57 protein tyrosine phosphatases 57 pharmacodynamic markers 57 PI3K signaling 57 underlying molecular mechanisms 57 candidemia 57 baseline LDH 57 Alternative splicing 57 commensal bacteria 57 metastatic prostate 57 MSMB 57 atherogenesis 57 hyperoxaluria 57 antiplatelet drugs 57 Candida infection 57 oncogenic transformation 57 HDAC enzyme 57 innate immune responses 57 genetic polymorphism 57 Hair follicle 57 cytolytic 57 clinically localized prostate 57 logistic regression analysis 57 Multiple logistic regression 57 Prognostic 57 B7 H4 57 allergenic protein 57 trans palmitoleate 57 FDG PET 57 biochemical marker 57 allogeneic HSCT 57 pretransplant 57 cell adhesion molecules 57 endocrine therapies 57 non pharmacological interventions 57 atherosclerosis regression 57 motor neuron degeneration 57 Cognitive impairment 57 glycolipids 57 pilocytic astrocytomas 57 Genotypic 57 developmental neurotoxicity 57 alpha7 NNR 57 ESBL producing 57 selenium supplementation 57 rheumatoid factor 57 antimetabolites 57 demonstrated antitumor activity 57 pharmacodynamic effects 57 ionic currents 57 phosphorylated proteins 57 bone scintigraphy 57 metabolomic profiling 57 virologic responses 57 aerodigestive tract 57 proximal colon 57 immunostimulatory effects 57 proto oncogene 57 haematological 57 renal cell carcinomas 57 papillary renal cell carcinoma 57 monoclonal gammopathy 57 colorectal tumor 57 aminopeptidase 57 thiopurine 57 BRAF V#E 57 hemodilution 57 #T# L1 57 nodal metastasis 57 cardioprotective effect 57 ALI ARDS 57 Angiotensin converting enzyme 57 infiltrative 57 AT1R 57 IGFBP 57 ELISPOT 57 anti leukemic 57 radiographic outcomes 57 PSA kinetics 57 bronchoalveolar lavage BAL 57 pathogenetic 57 rat hepatocytes 57 Ki# 57 TSH receptor 57 interleukin IL -# 57 lymphovascular invasion 57 nephron sparing surgery 57 histone code 57 residual confounding 57 aneuploid cells 57 prognostic biomarkers 57 EGFR expression 57 basal cell carcinoma BCC 57 cytopenias 57 imatinib Gleevec 57 myelomas 57 sarcosine 57 sonographic diagnosis 57 protein tyrosine phosphatase 57 thrombophilia 57 albumin excretion 57 NKG2D 57 Chronic pancreatitis 57 hyper IgE syndrome 57 grade cervical intraepithelial 57 amyloid deposition 57 MiCK assay 57 biomolecular interactions 57 noninflammatory 57 immunosuppressant therapy 57 Neisseria gonorrhoeae 57 elevated triglyceride levels 57 Apolipoprotein B 57 empiric therapy 57 nutrient supplementation 57 cardioprotective effects 57 coronary stenosis 57 intracellular signaling pathways 57 methodologically rigorous 57 branching morphogenesis 57 Velculescu 57 Thyroid hormone 57 steroidogenic 57 ultrastructural 57 histological subtypes 57 urine dipstick 57 mononuclear 57 oncogenic mutations 57 transcriptional machinery 57 TPMT 57 neuropsychological impairment 57 JAK inhibitors 57 metastatic lesions 57 elevated LDH 57 folate metabolism 57 autoantibody levels 57 breast carcinoma 57 idiopathic pulmonary 57 unmeasured factors 57 differentiating squamous 57 chronic periodontitis 57 leiomyoma 57 druggable targets 57 HSF1 57 pancreatic cysts 57 artifactual 57 carcinoembryonic antigen 57 LSD1 57 NSCLC tumors 57 immunoreactivity 57 multifactorial disease 57 glial tumors 57 GSOs 57 peptide antigens 57 conventional angiography 57 noncancerous cells 57 adjuvant systemic 57 pharmacogenetic testing 57 coronary microvascular 57 haplotyping 57 deacetylation 57 neuropilin 57 anaplastic 57 antiplatelet medications 57 P selectin 57 DACH platinum 57 etiological factors 57 eosinophil count 57 prognostic factors 57 neurotrophic 57 BRAF V# mutation 57 enzyme immunoassay EIA 57 metabolizing enzymes 57 chronic leukemias 57 PCNSL 57 artery stenosis 57 anti androgens 57 susceptibility loci 57 polycythemia vera PV 57 essential thrombocythemia 57 #q# deletion 57 evolvability 57 homocysteine concentrations 57 K ras 57 pancreatic ductal 57 normal karyotype 57 NPM1 gene 56 microarray gene expression 56 pathophysiological mechanisms 56 metabolic alterations 56 subclinical disease 56 splice variants 56 beta1 integrin 56 periprocedural MI 56 sporadic ALS 56 lung nodule 56 γ secretase 56 dose proportionality 56 percutaneous cryoablation 56 nodal dissection 56 microsatellite instability 56 bladder carcinoma 56 biochemical recurrence 56 biomarker validation 56 curability 56 central corneal thickness 56 BRAF inhibitors 56 trans retinoic acid 56 catheter angiography 56 pathophysiological 56 bacterial virulence 56 antiandrogens 56 troponin assay 56 tyrosine phosphorylation 56 perfusion imaging 56 ORMDL3 56 Histological 56 PIK3CA 56 thyrotropin 56 plasma pharmacokinetics 56 ADME properties 56 myocardial dysfunction 56 post translational modifications 56 androgen ablation 56 CIN2 + 56 colorectal neoplasms 56 postoperative morbidity 56 multigene 56 ALB # 56 therapeutic regimens 56 hypermethylated 56 airway responsiveness 56 breast carcinomas 56 anticancer therapy 56 TCF#L# gene 56 perfusion abnormalities 56 bronchoalveolar lavage fluid 56 neoplasms 56 Dr. Bezprozvanny 56 serum leptin 56 ascertainment bias 56 perilipin 56 immunofluorescent 56 d dimer 56 myelination disorders 56 EGFR pathway 56 transfect 56 iPS derived 56 chemopreventive agent 56 urease 56 ligand induced 56 poorer prognosis 56 Liver transplantation 56 antinuclear antibodies 56 HER2 positive breast 56 immuno suppressive 56 rifamycins 56 EGFR antibodies 56 myeloperoxidase 56 ADVEXIN therapy 56 carotid artery thickness 56 glycemia 56 synthetic lethality 56 PPARγ 56 unfavorable prognostic 56 Cathepsin B 56 fulvestrant 56 mitochondrial toxicity 56 adrenalectomy 56 Kaplan Meier curve 56 neurodevelopmental outcome 56 immune dysregulation 56 CD4 + T lymphocytes 56 multivariable analysis 56 atypical hyperplasia 56 Acute myeloid leukemia 56 cardiac repolarization 56 APTIMA HPV 56 stage IIIA 56 nucleotide analogs 56 eNO 56 teratogens 56 microRNA profiling 56 TNF α 56 isoenzyme 56 Immune responses 56 Aromatase 56 Tumor Response 56 Fas ligand 56 nitrotyrosine 56 RRM1 56 advanced adenomas 56 specific antigen PSA 56 intestinal biopsy 56 uPAR 56 troponins 56 C1q 56 astatine 56 cystatin 56 aetiological 56 PKCi 56 microarray experiments 56 oncogenesis 56 neurosensory 56 angiogenesis inhibition 56 HER2 amplification 56 cAMP signaling 56 neovascular 56 immunopathology 56 AhR 56 allele frequencies 56 PTEN gene 56 thrombogenic 56 fatty acid synthase 56 neuroregenerative 56 multiplexed assays 56 potentially modifiable 56 inverse agonist 56 qRT PCR 56 plasminogen activators 56 epigenetically 56 Vidofludimus 56 hs CRP 56 lung fibrosis 56 presymptomatic 56 COX2 56 NADPH oxidase 56 Chlamydia psittaci 56 Mathematical modeling 56 #S rRNA gene 56 thrombotic complications 56 aggregated Abeta 56 EGFR inhibitors 56 PCWP 56 thromboembolic disease 56 electrophysiological properties 56 sinonasal 56 glycosylated 56 biomarker assay 56 detecting colorectal cancer 56 pulmonary toxicity 56 cystatin C 56 MET amplification 56 assay detects 56 transgenic mouse models 56 fluconazole resistant 56 nephrogenic 56 costimulation 56 medically inoperable 56 CD4 + CD8 + 56 plexiform neurofibromas 56 JAK2 V#F 56 ADAMTS# 56 treating neuropathic pain 56 plasma renin activity 56 renal allograft 56 epithelia 56 NNRTI resistance 56 grade gliomas 56 posttranslational modification 56 superinfection 56 hemoglobins 56 autoregulation 56 NOD mouse 56 proton MR spectroscopy 56 antitumour 56 CFTR inhibitors 56 invasive carcinoma 56 metabolic abnormalities 56 intracranial hemorrhage ICH 56 pharmacokinetic characteristics 56 synovial tissue 56 C. difficile toxins 56 mechanistic explanation 56 differential diagnoses 56 Her2/neu 56 Adenomas 56 cerebellar vermis 56 hypothalamic pituitary 56 molecular determinants 56 Imprinted genes 56 CYP#D# gene